Filing Flows › BioXcel Therapeutics (BTAIQ) › Q1 2026
BioXcel Therapeutics (BTAIQ) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
BioXcel Therapeutics (BTAIQ) reported revenue of $206K for the first quarter 2026 (Q1 2026), +23% from a year earlier and -20% from the quarter before.
BioXcel Therapeutics, Q1 2026: revenue $206K (+23% year over year), net loss $12.7M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $206K | -20% | +23% |
| Operating profit | −$10.2M | — | — |
| Net earnings | −$12.7M | — | — |
| Operating cash flow | −$11.8M | — | — |
What changed
Revenue was $206K in Q1 2026, up 23% year over year and down 20% from the previous quarter.
Operating costs exceeded revenue by $10.2M, an operating margin of -4962.6%. Total costs grew 2% against revenue growth of 23%. The fastest-growing cost line was Cost of revenue (+1921%). The quarter ended with a net loss of $12.7M, wider than the previous quarter's $12.5M loss.
Operating cash flow was −$11.8M. Non-cash charges added back $58K of depreciation and $435K of share-based compensation.
Questions
What was BioXcel Therapeutics' revenue in the first quarter 2026?
BioXcel Therapeutics (BTAIQ) reported revenue of $206K for the first quarter 2026 (Q1 2026), +23% from a year earlier and -20% from the quarter before.